Long-term balance after chemotherapy (LTBAC)
Research type
Research Study
Full title
Long-term vestibular toxicity associated with cisplatin in adult survivors of cancer
IRAS ID
252550
Contact name
Pattarawadee Prayuenyong
Contact email
Sponsor organisation
Research and Innovation Nottingham University Hospitals NHS Trust
Duration of Study in the UK
1 years, 4 months, 28 days
Research summary
Cisplatin is an effective antineoplastic treatment for a variety of human cancers. Irreversible hearing loss was reported in 40-80% of patients treated with cisplatin; however, clinical research data on vestibular toxicity is very sparse. Vestibular organs of the inner ear play an important role in human balance system; consequently, exploration of vestibular side effects of cisplatin is worth conducting in this vulnerable group of patients. The purpose of this study is to evaluate the prevalence and impacts of vestibular and balance impairment in adult survivors of cancer who have received cisplatin. In this study, we will recruit testicular or gynaecologic cancer patients aged 18-60 years old who have completed cisplatin treatment for at least 6 months at the Oncology Clinics, City Hospital, Nottingham University Hospitals NHS Trust. These results will enable us to inform future clinical practice and create better holistic patient care.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
18/EM/0369
Date of REC Opinion
10 Dec 2018
REC opinion
Further Information Favourable Opinion